InfuSystem : Investor Presentation

Helping People Live Longer and

Healthier Lives

Investor Presentation

September 14, 2023 l (NYSE American: INFU)

Forward-Looking Statements / Non-GAAP Measures

Forward-Looking Statements

Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements relating to future actions, our share repurchase program and capital allocation strategy, business plans, strategic partnerships, growth initiatives, objectives and prospects, future operating or financial performance, guidance and expected new business relationships and the terms thereof (including estimated potential revenue under new or existing contracts). The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "goal," "expect," "strategy," "future," "likely," variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. Forward-looking statements are subject to factors, risks and uncertainties that could cause actual results to differ materially, including, but not limited to, our ability to successfully execute on our growth initiatives and strategic partnerships, our ability to enter into definitive agreements for the new business relationships on expected terms or at all, our ability to generate estimated potential revenue amounts under new or existing contracts, the uncertain impact of the COVID-19 pandemic, our dependence on estimates of collectible revenue, potential litigation, changes in third-party reimbursement processes, changes in law, global financial conditions and recessionary risks, rising inflation and interest rates, supply chain disruptions, systemic pressures in the banking sector, including disruptions to credit markets, the Company's ability to remediate its previously disclosed material weaknesses in internal control over financial reporting, contributions from acquired businesses or new business lines, products or services and other risk factors disclosed in the Company's most recent annual report on Form 10-K and, to the extent applicable, quarterly reports on Form 10-Q. Our strategic partnerships are subject to similar factors, risks and uncertainties. All forward-looking statements made in this presentation speak only as of the date hereof. InfuSystem does not undertake any obligation to update any forward-looking statements to reflect future events or circumstances, except as required by law.

Non-GAAP Measures

This presentation contains information prepared in conformity with GAAP as well as non-GAAP financial information. The Company believes that the non-GAAP financial measures presented in this presentation provide useful information to the Company's management, investors and other interested parties about the Company's operating performance because they allow them to understand and compare the Company's operating results during the current periods to the prior year periods in a more consistent manner. This non-GAAP information should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP, and similarly titled non-GAAP measures may be calculated differently by other companies. The Company calculates those non-GAAP measures by adjusting for nonrecurring or non-core items that are not part of the normal course of business and that the Company's management does not believe will have similar comparable year-over-year items. A reconciliation of those measures to the most directly comparable GAAP measures is provided in Appendix A of this presentation.

2

Investment Highlights	Facilitating Outpatient Care, Lowering the Cost
	Delivering Solutions Promoting Healing,
	of Care and Improving Patient Outcomes.

Enterprise Value*	Market Cap*	Shares Out
$246M	$210M	21.2M

	Net Revenues	2022 Adjusted	2022 Revenue
	$100.0			$97.4	$102.4	$109.9	EBITDA $20.7M	$109.9M, Up 7% y/y
	$120.0
Millions	$80.0		$81.1
$67.1
	$60.0							Driving
In	$40.0
						Shareholder
	$20.0
							Value
	$-	2018	2019	2020	2021	2022

*Market data as of September 7, 2023

3

Investment Highlights

37-Year History | Long-Term Blue Chip Customer Base

• Four Consecutive Years of Record Revenue
• • Revenue CAGR: 13%
  • Adjusted EBITDA CAGR: 11%

Business Generates Substantial Annual Cash Flow

• $17.5M - 2022 Cash Flow Provided by Operations Solid Balance Sheet to Support Growth
• Net Leverage Ratio: 1.71x
• Debt/Equity Ratio: 1.06x

$20M Stock Repurchase Program

• ~$14M Remaining Balance as of 6/30/2023 Medical Equipment Assets: ~$100M NOLs: ~$35.7M

*Data as of June 30, 2023, unless otherwise noted

4

Business Highlights

A leading provider of medical equipment and patient services powered by a 100K+ device fleet in the U.S. and Canada

Participating in-network provider in more than 800 health insurance networks covering over 96% of the U.S. population, serving over 2,450 sites of care

Over three decades of experience, built on existing Oncology therapy model and now rapidly expanding into multiple therapies

	Seven major
Serving nearly	service areas in
the U.S. and
5,000 customer
Canada with
locations
more than 450
	employees

National scale, serving 18 out of

20 top-ranked hospital systems nationwide*

*Source: U.S. News & World Report, Best Hospitals, July 2022

5